Streetbeat News

Analyst Ratings

GAMB

Macquarie analyst Chad Beynon has initiated coverage on Gambling.com Gr (NASDAQ:GAMB) with an Outperform rating and a price target of $13.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 1:41 pm

AZO

Northcoast Research analyst Aaron Reed has initiated coverage on AutoZone (NYSE:AZO) with a Neutral rating.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 1:39 pm

AAP

Northcoast Research analyst Aaron Reed has initiated coverage on Advance Auto Parts (NYSE:AAP) with a Neutral rating.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 1:38 pm

GPC

Northcoast Research analyst Aaron Reed has initiated coverage on Genuine Parts (NYSE:GPC) with a Buy rating and a price target of $195.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 1:38 pm

ARRY

Janney Montgomery Scott has initiated coverage on Array Technologies (NASDAQ:ARRY) with a Buy rating and a price target of $37.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 1:33 pm

SSTI

Cantor Fitzgerald analyst Jonathan Ruykhaver has initiated coverage on SoundThinking (NASDAQ:SSTI) with an Overweight rating and a price target of $30.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 1:32 pm

GS

RBC Capital analyst Gerard Cassidy has reiterated a 'Sector Perform' rating on Goldman Sachs Gr (NYSE:GS) and maintained a price target of $375.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 1:27 pm

SNX

RBC Capital analyst Ashish Sabadra maintains a 'Sector Perform' rating on TD Synnex (NYSE:SNX) and lowers the price target from $110 to $98.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 1:27 pm

REGN

RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on Regeneron Pharmaceuticals (NASDAQ:REGN) but lowered the price target from $816 to $789.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 1:26 pm

EWTX

RBC Capital analyst Leonid Timashev has reiterated his 'Outperform' rating on Edgewise Therapeutics (NASDAQ:EWTX), maintaining a price target of $28.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 1:25 pm